Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents

This publication has 30 references indexed in Scilit:

• Treating diabetes today: a matter of selectivity of sulphonylureas
  Diabetes, Obesity and Metabolism, 2011
• Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
  European Heart Journal, 2011
• A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study
  Diabetic Medicine, 2010
• Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes
  Hormone and Metabolic Research, 2009
• Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
  New England Journal of Medicine, 2008
• Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
  New England Journal of Medicine, 2006
• Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone
  Diabetic Medicine, 2006
• The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes)
  Diabetes, Obesity and Metabolism, 2004
• Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide
  Biochemical and Biophysical Research Communications, 2003
• Worldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis
  Diabetes/Metabolism Research and Reviews, 1995